28.49
price down icon3.29%   -0.97
pre-market  Pre-mercato:  28.87   0.38   +1.33%
loading
Precedente Chiudi:
$29.46
Aprire:
$29.46
Volume 24 ore:
873.15K
Relative Volume:
0.99
Capitalizzazione di mercato:
$2.19B
Reddito:
$13.17M
Utile/perdita netta:
$-199.06M
Rapporto P/E:
-10.40
EPS:
-2.74
Flusso di cassa netto:
$-156.53M
1 W Prestazione:
-6.47%
1M Prestazione:
-24.71%
6M Prestazione:
-33.97%
1 anno Prestazione:
-26.21%
Intervallo 1D:
Value
$28.44
$29.68
Intervallo di 1 settimana:
Value
$28.44
$31.23
Portata 52W:
Value
$26.74
$46.00

Xenon Pharmaceuticals Inc Stock (XENE) Company Profile

Name
Nome
Xenon Pharmaceuticals Inc
Name
Telefono
(604) 484-3300
Name
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Name
Dipendente
327
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
XENE's Discussions on Twitter

Confronta XENE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
XENE
Xenon Pharmaceuticals Inc
28.49 2.34B 13.17M -199.06M -156.53M -2.74
Biotechnology icon
ONC
Beigene Ltd Adr
240.41 25.57B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.10 111.79B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.30 39.90M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
591.85 65.28B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
73.93 6.31B 0 -153.72M -103.81M -2.00

Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-07 Iniziato Chardan Capital Markets Buy
2025-02-11 Iniziato Deutsche Bank Buy
2024-10-10 Ripresa Raymond James Outperform
2024-10-01 Iniziato H.C. Wainwright Buy
2024-01-04 Iniziato Citigroup Buy
2023-12-08 Iniziato Robert W. Baird Outperform
2023-10-24 Ripresa Cantor Fitzgerald Overweight
2023-04-25 Iniziato Cantor Fitzgerald Overweight
2022-12-14 Iniziato Goldman Buy
2022-12-12 Iniziato Cowen Outperform
2022-11-28 Iniziato Wells Fargo Overweight
2022-10-19 Iniziato Raymond James Outperform
2022-08-29 Iniziato BofA Securities Buy
2022-07-21 Iniziato JP Morgan Overweight
2021-10-28 Iniziato RBC Capital Mkts Outperform
2020-10-02 Iniziato SVB Leerink Outperform
2020-07-21 Iniziato Needham Buy
2020-06-01 Ripresa Jefferies Buy
2020-03-25 Iniziato Wedbush Outperform
2020-01-08 Iniziato William Blair Outperform
2019-09-20 Iniziato Guggenheim Buy
2018-08-08 Reiterato Stifel Buy
2017-03-13 Iniziato Jefferies Buy
2016-10-21 Iniziato Stifel Buy
2016-09-26 Iniziato Guggenheim Buy
2016-04-14 Reiterato Jefferies Buy
2015-10-30 Ripresa Jefferies Buy
2014-12-02 Iniziato Canaccord Genuity Buy
Mostra tutto

Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie

pulisher
03:28 AM

Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - Defense World

03:28 AM
pulisher
May 27, 2025

Ameriprise Financial Inc. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World

May 27, 2025
pulisher
May 26, 2025

(XENE) Investment Analysis and Advice - news.stocktradersdaily.com

May 26, 2025
pulisher
May 25, 2025

Northern Trust Corp Raises Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World

May 25, 2025
pulisher
May 23, 2025

Xenon Pharmaceuticals (NASDAQ:XENE) Rating Lowered to “Sell” at Wall Street Zen - Defense World

May 23, 2025
pulisher
May 21, 2025

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

May 21, 2025
pulisher
May 20, 2025

Xenon Pharmaceuticals’ SWOT analysis: neurological drug stock faces pivotal year - Investing.com India

May 20, 2025
pulisher
May 18, 2025

Analysts Issue Forecasts for XENE FY2025 Earnings - Defense World

May 18, 2025
pulisher
May 17, 2025

Leerink Partnrs Has Bullish Forecast for XENE Q2 Earnings - Defense World

May 17, 2025
pulisher
May 16, 2025

XENE FY2025 EPS Estimate Decreased by Cantor Fitzgerald - Defense World

May 16, 2025
pulisher
May 16, 2025

What is William Blair’s Estimate for XENE FY2025 Earnings? - Defense World

May 16, 2025
pulisher
May 16, 2025

Xenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated at Evercore ISI - Defense World

May 16, 2025
pulisher
May 16, 2025

HC Wainwright Issues Optimistic Outlook for XENE Earnings - Defense World

May 16, 2025
pulisher
May 15, 2025

How To Trade (XENE) - news.stocktradersdaily.com

May 15, 2025
pulisher
May 15, 2025

Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World

May 15, 2025
pulisher
May 15, 2025

Chardan Capital Reiterates “Buy” Rating for Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World

May 15, 2025
pulisher
May 15, 2025

Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World

May 15, 2025
pulisher
May 15, 2025

Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus - MSN

May 15, 2025
pulisher
May 15, 2025

Needham & Company LLC Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $55.00 - Defense World

May 15, 2025
pulisher
May 15, 2025

Wells Fargo & Company Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - Defense World

May 15, 2025
pulisher
May 15, 2025

Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Upgraded by StockNews.com - Defense World

May 15, 2025
pulisher
May 14, 2025

Evercore ISI Group Initiates Coverage of Xenon Pharmaceuticals (XENE) with Outperform Recommendation - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Xenon signals Phase 3 epilepsy readout in early 2026 with expanded pipeline advancements - MSN

May 14, 2025
pulisher
May 14, 2025

Xenon Pharmaceuticals to Present at 2025 RBC Healthcare Conference - TipRanks

May 14, 2025
pulisher
May 14, 2025

Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference - The Manila Times

May 14, 2025
pulisher
May 14, 2025

Xenon CEO to Showcase Revolutionary Late-Stage Epilepsy Treatment: Key Updates Coming at RBC Conference - Stock Titan

May 14, 2025
pulisher
May 14, 2025

XENE: Evercore ISI Group Initiates Coverage with 'Outperform' Ra - GuruFocus

May 14, 2025
pulisher
May 14, 2025

XENE: Evercore ISI Group Initiates Coverage with 'Outperform' Rating | XENE Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday - Insider Monkey

May 14, 2025
pulisher
May 14, 2025

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025
pulisher
May 14, 2025

XENE: Wells Fargo Adjusts Price Target for Xenon Pharmaceuticals - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Xenon Pharmaceuticals (XENE) Price Target Adjusted by Analyst | - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down After Analyst Downgrade - Defense World

May 14, 2025
pulisher
May 14, 2025

XENE: HC Wainwright Reiterates Buy Rating for Xenon Pharmaceuticals | XENE Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

XENE: RBC Capital Adjusts Price Target as Xenon Pharmaceuticals Faces Timeline Shift | XENE Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

XENE: Analyst Reaffirms Buy Rating with Price Target of $55 | XE - GuruFocus

May 14, 2025
pulisher
May 14, 2025

XENE Price Target Revised Following Earnings and Data Delay | XE - GuruFocus

May 14, 2025
pulisher
May 14, 2025

XENE: Needham Adjusts Price Target on Xenon Pharmaceuticals | XE - GuruFocus

May 14, 2025
pulisher
May 13, 2025

XENE: RBC Capital Lowers Xenon Pharmaceuticals Price Target | XE - GuruFocus

May 13, 2025
pulisher
May 13, 2025

FOS-tering patience: Xenon moves azetukalner data to next year - BioWorld MedTech

May 13, 2025
pulisher
May 13, 2025

Xenon Pharmaceuticals stock falls on delayed study results By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

Xenon Pharmaceuticals stock falls on delayed study results - Investing.com Australia

May 13, 2025
pulisher
May 13, 2025

Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position ... - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlight - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position and Promising Clinical Developments - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Xenon Pharmaceuticals Advances Clinical Programs Amid Financial Loss - TipRanks

May 13, 2025
pulisher
May 12, 2025

Xenon Pharmaceuticals Reports Q1 2025 Results and Advances Clinical Pipeline - TipRanks

May 12, 2025
pulisher
May 12, 2025

XENE: Xenon Advances Phase 3 Programs in Epilepsy and Psychiatry | XENE Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings: EPS Loss of $0.83 Beats Estimate, Revenue Soars to $7.5 Million - GuruFocus

May 12, 2025
pulisher
May 12, 2025

XENON PHARMACEUTICALS Earnings Results: $XENE Reports Quarterly Earnings - Nasdaq

May 12, 2025
pulisher
May 12, 2025

Xenon Pharmaceuticals: Q1 Earnings Snapshot - San Antonio Express-News

May 12, 2025

Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Xenon Pharmaceuticals Inc Azioni (XENE) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
MORTIMER IAN
PRESIDENT & CEO
Jan 24 '25
Option Exercise
17.76
22,468
399,032
53,770
MORTIMER IAN
PRESIDENT & CEO
Jan 27 '25
Option Exercise
17.76
16,315
289,754
46,468
MORTIMER IAN
PRESIDENT & CEO
Jan 23 '25
Option Exercise
17.76
16,217
288,014
47,519
MORTIMER IAN
PRESIDENT & CEO
Jan 24 '25
Sale
40.20
22,468
903,214
31,302
MORTIMER IAN
PRESIDENT & CEO
Jan 27 '25
Sale
40.50
16,315
660,806
31,302
MORTIMER IAN
PRESIDENT & CEO
Jan 23 '25
Sale
40.08
16,217
649,977
31,302
$1.05
price down icon 8.70%
$30.28
price down icon 2.39%
$576.24
price down icon 0.61%
$285.56
price down icon 1.56%
$4.35
price up icon 1.64%
$73.93
price down icon 2.22%
Capitalizzazione:     |  Volume (24 ore):